July 16, 2025 09:47 AM EDT

Drugs! In! Space! After years of hype, are biopharma and rockets finally going to do something?

Drew Armstrong

Executive Editor

I am a classic low-information drugs-in-space skeptic. For years — years — I have been reading stories about how some tiny biotech, a research lab or a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Drugs! In! Space! After years of hype, are biopharma and rockets finally going to do something?

Drew Armstrong

Executive Editor

Sign up to read this article for free.

PureTech CEO leaves just one week after longtime chair steps down

Sarepta adds black box warning to its Duchenne treatment, cuts 500 workers

RFK reshuffles top HHS leadership, replacing his chief of staff and another top aide

Prime Medicine CSO departs, reveals new funding; FDA lifts partial hold on Kezar drug

Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future

Prasad again overrode FDA vaccine reviewers, this time on Moderna’s Covid shot for young kids

Drugs! In! Space! Af­ter years of hype, are bio­phar­ma and rock­ets fi­nal­ly go­ing to do some­thing?

Drew Armstrong

Executive Editor

Sign up to read this article for free.

more like this

PureTech CEO leaves just one week af­ter long­time chair steps down

Sarep­ta adds black box warn­ing to its Duchenne treat­ment, cuts 500 work­ers

RFK reshuf­fles top HHS lead­er­ship, re­plac­ing his chief of staff and an­oth­er top aide

Prime Med­i­cine CSO de­parts, re­veals new fund­ing; FDA lifts par­tial hold on Kezar drug

Up­dat­ed: FDA pub­lish­es repos­i­to­ry of 200+ drug re­jec­tion let­ters, promis­ing more in the fu­ture

Prasad again over­rode FDA vac­cine re­view­ers, this time on Mod­er­na’s Covid shot for young kids

Drugs! In! Space! After years of hype, are biopharma and rockets finally going to do something?

PureTech CEO leaves just one week after longtime chair steps down

Sarepta adds black box warning to its Duchenne treatment, cuts 500 workers

RFK reshuffles top HHS leadership, replacing his chief of staff and another top aide

Prime Medicine CSO departs, reveals new funding; FDA lifts partial hold on Kezar drug

Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future

Prasad again overrode FDA vaccine reviewers, this time on Moderna’s Covid shot for young kids